Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

Single nucleotide polymorphisms (SNPs) in the estrogen receptor 1 (ESR1) and cytochrome P450 19A1 (CYP19A1) genes have been associated with breast cancer risk, endocrine therapy response and side effects, mainly in postmenopausal women with early breast cancer. This analysis aimed to assess the asso...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research : BCR 2016-11, Vol.18 (1), p.110, Article 110
Hauptverfasser:	Johansson, Harriet, Gray, Kathryn P, Pagani, Olivia, Regan, Meredith M, Viale, Giuseppe, Aristarco, Valentina, Macis, Debora, Puccio, Antonella, Roux, Susanne, Maibach, Rudolf, Colleoni, Marco, Rabaglio, Manuela, Price, Karen N, Coates, Alan S, Gelber, Richard D, Goldhirsch, Aron, Kammler, Roswitha, Bonanni, Bernardo, Walley, Barbara A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Aromatase - genetics Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - mortality Clinical Trials, Phase III as Topic Complications and side effects Drug-Related Side Effects and Adverse Reactions - genetics Estrogen Receptor alpha - genetics Female Genetic Variation Health aspects Hormone therapy Hot Flashes - genetics Humans Middle Aged Odds Ratio Pharmacogenomic Variants Postmenopausal women Randomized Controlled Trials as Topic Risk Factors Single nucleotide polymorphisms Sweating - genetics Tamoxifen
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!